Your rheumatologist might bring up new guidelines at your next visit, and you deserve to know what they actually mean before you walk in. In March 2026, a EULAR guideline update was made. The European Alliance of Associations for Rheumatology (EULAR) released its newest update to the guidelines doctors use to treat rheumatoid arthritis. The short version: the update simplifies the treatment roadmap, reinforces some long-standing habits, and adds a clearer stance on staying on your medication once it’s working. Nothing here changes your diagnosis. It changes how confidently your care team can build your treatment plan.
Let’s break down what actually shifted and why it matters for you.
A Quick Recap: What Is EULAR, and Why Should You Care?
EULAR first published RA management guidelines in 2010. Rheumatologists across the world use them as a north star for treatment decisions. This 2026 release marks the fifth update in that 15-year history, and it’s the leanest one yet. The task force trimmed the individual recommendations from 11 down to 9, merging two and cutting one entirely. Fewer recommendations doesn’t mean less guidance. It means the guidance is tighter and easier for your care team to apply.
The update also leans on a new visual algorithm. Think of it as a flowchart your rheumatologist can walk through with you, matching your disease activity and history to the next right step.
What Actually Changed
DMARDs still start right away
The guidelines reaffirm that disease-modifying antirheumatic drugs (DMARDs) should begin as soon as an RA diagnosis is confirmed. Early treatment continues to give you the best shot at controlling inflammation before it causes lasting joint damage. Methotrexate remains the recommended first-line therapy for most patients.
A stronger stance on staying the course
This is the update’s biggest practical shift. Previous guidelines said patients in sustained remission could consider reducing their DMARD dose after stopping glucocorticoids. The new version now favors continuing your current medication, though dose reduction is still on the table in the right circumstances. Task force leaders pointed to a clear pattern: stopping treatment altogether, especially biologics or JAK inhibitors, tends to bring flares back. If you’ve been feeling great and wondering whether you still need your infusions, this update answers that question directly. Consistency protects the progress you’ve made.
Treatment failure now stands on its own
Previously, if your first treatment strategy didn’t work, your care team would also weigh separate risk factors for poor long-term outcomes. The new guidelines drop that extra layer. A failed first strategy now counts as its own warning sign. Your rheumatologist can move you to the next option without waiting on additional risk scoring. It’s one less hurdle between you and a treatment adjustment that actually works.
Your care stays a two-way conversation
Every version of these guidelines has emphasized shared decision-making, and 2026 is no exception. Your rheumatologist should walk you through the options and factor in your disease activity, safety concerns, other health conditions, and personal preferences. You may need several different therapies over your lifetime as your disease and circumstances change. That’s normal. It’s not a sign that something has gone wrong.
What This Means If You’re On Infusion Therapy
If you already receive biologic infusions for RA, this update mostly reinforces your current path rather than upending it. The emphasis on staying with an effective treatment, rather than tapering off once you feel good, lines up with what your infusion team likely already recommends. If a treatment stops working the way it used to, these guidelines make it easier for your rheumatologist to move you to the next option without delay.
We treat rheumatoid arthritis and related conditions at our infusion center. We coordinate closely with referring rheumatologists on exactly these kinds of treatment decisions. Guideline updates like this one shape the conversations we have with your care team every day.
The Bottom Line
The 2026 EULAR guideline update doesn’t reinvent RA treatment. It sharpens it. Start treatment early, stick with what’s working, and skip unnecessary extra steps when a strategy needs to change. If you have questions about your own treatment plan, this is a good moment to bring them up with your rheumatologist.
Ready to Talk About Your Treatment Plan?
Guideline updates are a great conversation starter. Your primary care physician or rheumatologist is the right person to review your diagnosis and refer you for treatment. Once you have that referral, our team is glad to help. If you have any questions about infusion therapy, what to expect, or how we work with your care team, contact us any time. You can also learn more about who we are and what we offer or see what other patients say by checking our Google reviews.
Frequently Asked Questions about the EULAR Guideline Update
Does the 2026 EULAR update mean my RA treatment will change?
Not automatically. The update mainly reinforces early treatment and staying consistent with medication that’s working. Your rheumatologist will decide if any change applies to your specific case.
Why do the new guidelines recommend against stopping medication during remission?
Task force researchers found that stopping treatment entirely, especially biologics or JAK inhibitors, often leads to flares. The updated guidance favors continuing treatment, with dose reduction still possible in some cases.
Do I need a new referral to start infusion therapy?
Yes. Your primary care physician or rheumatologist needs to confirm your diagnosis and provide a referral before infusion therapy can begin. From there, our team handles authorization and scheduling.